Following the successful completion of its deal to acquire GSK’s opiates business in Australia, Sun Pharmaceutical Industries Ltd has begun the process of integration of the acquired business. This deal, first announced in March 2015, fortifies Sun Pharma’s global position with two opiates manufacturing facilities in Port Fairy & Latrobe (both in Australia) complementing its current API manufacturing footprint globally.
Sun Pharma now offers a rich basket of opiates product line in addition to a large API portfolio and dosage formulations covering a broad range of chronic and acute prescription drugs. The acquisition also brings a specialised team to drive business growth. Opiates are any of the opioid analgesic alkaloids found as natural products in the opium poppy plant, Papaver somniferum.
The opiates acquisition allows Sun Pharma to significantly expands its narcotics raw material (NRM) market share; enhance opiate alkaloids portfolio & depth in global opiates market; and strengthen its strategic position in the global opiates business.
Anil Kumar Jain, CEO – API business, Sun Pharma, said, “The successful completion of this acquisition enables us to leverage our unique position in the global opiates business by capitalising our global footprint and global ranking in the specialty generics market. Sun Pharma stays committed to uncompromised product quality, 100% compliance and innovation.”
Source: Business Standard
Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.
Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.
The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).
